Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 511 Lobo Lane LITTLE ELM TX 75068-5295 |
Tel: | 1-972-2941010 |
Website: | https://retractable.com |
IR: | See website |
Key People | ||
Thomas J. Shaw Chairman of the Board, President, Chief Executive Officer, Founder | John W. Fort Chief Financial Officer, Vice President, Treasurer, Director | Michele M. Larios Vice President, General Counsel, Secretary |
Business Overview |
Retractable Technologies, Inc. is engaged in manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. The Company is focused on the production of injection devices (syringes and needles). Such products are marketed under the VanishPoint, Patient Safe, and EasyPoint brands. The VanishPoint syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint needle can also be used to aspirate fluids and for blood collection. Its products are distributed by various specialty and general line distributors. |
Financial Overview |
For the fiscal year ended 31 December 2023, Retractable Technologies Inc revenues decreased 54% to $43.6M. Net loss applicable to common stockholders totaled $7.2M vs. income of $4.8M. Revenues reflect North and South America(excluding U.S) segment decrease of 79% to $6.1M, Other International segment decrease of 78% to $2.9M. Net loss reflects Unrealized gain (loss) on debt and equit decrease from $2.3M (income) to $10.5M (expense). |
Employees: | 148 as of Mar 11, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $43.60M as of Dec 31, 2023 |
EBITDA (TTM): | -$3.96M as of Dec 31, 2023 |
Net annual income (TTM): | -$7.24M as of Dec 31, 2023 |
Free cash flow (TTM): | $1.68M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 29,937,159 as of Mar 11, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |